Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and data in the world of biotech ...

2024年10月28日 · OS Therapies acquired the rights to Ayala’s Listeria monotygenes-based immuno-oncology programs for $500,000 in cash and $7.5 million in stock.

2 天之前 · A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. | The Fierce Biotech Fundraising Tracker records ...

6 天之前 · 2024 saw a healthier IPO market than 2023, with activity triggered by M&A that occurred in the back end of '23, Morgan Stanley's Chirag Surti said.

12 小时之前 · Roche has pursued a multifront attack on FAP, studying CD40 and DR5 bispecifics, respectively RG6189 and RG7386, and the immunocytokine RG7461, but dropped those assets over time.

One of our Fierce 15 honorees dove deep into the ocean for inspiration from the sea squirt to develop new human therapeutics. Another thought the adorable 13-lined ground squirrel, with its polka ...

2024年12月23日 · Fierce Biotech's Gabrielle Masson presents Fierce 15 at NYSE. Unveiling the Fierce 15 list is always a high point of our year, as we run down the 15 companies breaking barriers and defining the ...

Biopharma is a fast-growing world where big ideas come along daily. Our readers rely on Fierce Biotech for the latest news, analysis and data on drugs and the companies that make them.

This yea'rs Fierce 15 features companies pushing the envelope not only in the lab, in the clinic or on the conference circuit.

2024年12月6日 · To learn more about the topics in this episode: Septerna's $288M IPO is another sign of the market warming to biotech investment; BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq